Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell H Rosner

Showing results (71-80 of 205) with videos related to

Pageof 21
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN|August 8, 2008
The agony of ecstasy: MDMA (3,4-methylenedioxymethamphetamine) and the kidneyGarland A Campbell, Mitchell H Rosner
Clinical Journal of the American Society of Nephrology : CJASN|September 1, 2012
Onco-nephrology: what the nephrologist needs to know about cancer and the kidneyJeffrey S Berns, Mitchell H Rosner
Archives of Internal Medicine|May 14, 2003
Combination therapy with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in the treatment of patients with type 2 diabetes mellitusMitchell H Rosner, Mark D Okusa
Journal of Nephrology|May 22, 2017
Influenza and the patient with end-stage renal diseaseBrendan T Bowman, Mitchell H Rosner
Intensive Care Medicine|April 26, 2017
Have biomarkers failed in acute kidney injury? We are not sureJohn R Prowle, Mitchell H Rosner
Kidney International|September 24, 2018
"Highlighting" an unusual case of discolored peritoneal dialysis effluentSana F Khan, Mitchell H Rosner
Drugs of Today (Barcelona, Spain : 1998)|February 4, 2010
Ferumoxytol for the treatment of anemia in chronic kidney diseaseMitchell H Rosner, W Kline Bolton
Core Evidence|July 23, 2013
Lixivaptan - an evidence-based review of its clinical potential in the treatment of hyponatremiaBrendan T Bowman, Mitchell H Rosner
European Journal of Internal Medicine|July 29, 2023
Corrigendum to 'Creatinine: From physiology to clinical application'[European Journal of Internal Medicine 72C (2020) 9-14]Kianoush Kashani, Mitchell H Rosner, Marlies Ostermann
Drugs & Aging|August 18, 2017
Drug-Induced Kidney Injury in the ElderlySana Khan, Valentina Loi, Mitchell H Rosner
Pageof 21

Showing results (71-80 of 205) with videos related to

Sort By:
Pageof 21
Clinical Journal of the American Society of Nephrology : CJASN|August 8, 2008
The agony of ecstasy: MDMA (3,4-methylenedioxymethamphetamine) and the kidneyGarland A Campbell, Mitchell H Rosner
Clinical Journal of the American Society of Nephrology : CJASN|September 1, 2012
Onco-nephrology: what the nephrologist needs to know about cancer and the kidneyJeffrey S Berns, Mitchell H Rosner
Archives of Internal Medicine|May 14, 2003
Combination therapy with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in the treatment of patients with type 2 diabetes mellitusMitchell H Rosner, Mark D Okusa
Journal of Nephrology|May 22, 2017
Influenza and the patient with end-stage renal diseaseBrendan T Bowman, Mitchell H Rosner
Intensive Care Medicine|April 26, 2017
Have biomarkers failed in acute kidney injury? We are not sureJohn R Prowle, Mitchell H Rosner
Kidney International|September 24, 2018
"Highlighting" an unusual case of discolored peritoneal dialysis effluentSana F Khan, Mitchell H Rosner
Drugs of Today (Barcelona, Spain : 1998)|February 4, 2010
Ferumoxytol for the treatment of anemia in chronic kidney diseaseMitchell H Rosner, W Kline Bolton
Core Evidence|July 23, 2013
Lixivaptan - an evidence-based review of its clinical potential in the treatment of hyponatremiaBrendan T Bowman, Mitchell H Rosner
European Journal of Internal Medicine|July 29, 2023
Corrigendum to 'Creatinine: From physiology to clinical application'[European Journal of Internal Medicine 72C (2020) 9-14]Kianoush Kashani, Mitchell H Rosner, Marlies Ostermann
Drugs & Aging|August 18, 2017
Drug-Induced Kidney Injury in the ElderlySana Khan, Valentina Loi, Mitchell H Rosner
Pageof 21